APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. (September 2017) - Mehdi, Delphine El; Grossi, Federico V.; Deschatelets, Pascal; Pullon, Humphrey; Tan, Lisa; Vega, Carolina A.; Francois, Cedric G.